Multi-institutional comparison of 99mTc-MAA lung shunt fraction for transcatheter Y-90 radioembolization. New Orleans, LA: Presented at the Annual Meeting of the Society of Interventional Radiology, 2005.
Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies. J Am Pharm Assoc (Wash) 2000;40:46-51.
Yttrium-90 microsphere therapy for hepatic malignancy: Devices, indications, technical considerations and potential complications. Radiographics 2005;25(suppl 1):S41-S55.
Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (Thera Sphere): Assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006;9:522-29.
Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol 2004;19:347-49.
Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 2004;3:49-56.
Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011 Jun;22(6):780-86.
Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol 2010 Aug;21(8):1213-18.
Proximal arterio portal shunting associated with hepatocellular carcinoma: Features revealed by dynamic helical CT. AJR 1999;172:403-07.